Cargando…

COVID-19 mRNA vaccines: Platforms and current developments

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine agent in a preclinical study nearly 30 years ago, numerous advances have been made in the field of mRNA therapeutic technologies. This research uncovered the unique favorable characteristics of mRNA vaccines, in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szabó, Gábor Tamás, Mahiny, Azita Josefine, Vlatkovic, Irena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856755/ https://www.ncbi.nlm.nih.gov/pubmed/35189345 http://dx.doi.org/10.1016/j.ymthe.2022.02.016

Ejemplares similares

Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA
por: Vlatkovic, Irena, et al.
Publicado: (2022)

A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA
por: Baiersdörfer, Markus, et al.
Publicado: (2019)

ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model
por: Daly, Owen, et al.
Publicado: (2023)

Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety
por: Vlatkovic, Irena
Publicado: (2021)

mRNA Vaccine Platform: mRNA Production and Delivery
por: Litvinova, V. R., et al.
Publicado: (2023)

Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development
por: Schmidt, Christin, et al.
Publicado: (2023)

Advances in COVID-19 mRNA vaccine development
por: Fang, Enyue, et al.
Publicado: (2022)

Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?
por: Fedorowski, Jaroslaw J.
Publicado: (2021)

COVID-19 mRNA vaccines
por: Huang, Qingrui, et al.
Publicado: (2021)

COVID-19 mRNA Vaccination
por: Vered, Livneh, et al.
Publicado: (2022)

Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections
por: Versteeg, Leroy, et al.
Publicado: (2019)

Future considerations for the mRNA-lipid nanoparticle vaccine platform
por: Igyártó, Botond Z, et al.
Publicado: (2021)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
por: Chellapandian, Suresh Babu, et al.
Publicado: (2022)

Lipid nanoparticles in the development of mRNA vaccines for COVID-19
por: Wilson, Barnabas, et al.
Publicado: (2022)

The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism
por: Lazaros, George, et al.
Publicado: (2021)

The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response
por: Kapnick, Senta M.
Publicado: (2022)

Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials
por: Whitley, Jill, et al.
Publicado: (2022)

mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
por: Xu, Shuqin, et al.
Publicado: (2020)

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
por: Rouf, Nusrat Zahan, et al.
Publicado: (2022)

mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
por: Ilyichev, A.A., et al.
Publicado: (2020)

Shingles and mRNA COVID‐19 vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Commentary of the mRNA vaccines COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021)

Myocarditis and COVID-19 mRNA vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

COVID-19 mRNA Vaccine and Myocarditis
por: Singh, Balraj, et al.
Publicado: (2021)

COVID‐19 mRNA vaccines and myopericarditis
por: Gnanenthiran, Sonali R., et al.
Publicado: (2022)

The Risk of Autoimmunity Development following mRNA COVID-19 Vaccination
por: Świerkot, Jerzy, et al.
Publicado: (2022)

The Rise of mRNA COVID-19 Vaccine-Associated Myocarditis and Its Implications on the Future Use of This New Vaccine Platform
por: Anthony, Jamal A, et al.
Publicado: (2022)

Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
por: Rohde, Cynthia M., et al.
Publicado: (2023)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
por: Parés-Badell, Oleguer, et al.
Publicado: (2022)

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
por: Hajissa, Khalid, et al.
Publicado: (2021)

Literature Mining and Mechanistic Graphical Modelling to Improve mRNA Vaccine Platforms
por: Leonardelli, Lorena, et al.
Publicado: (2021)

Development and Delivery Systems of mRNA Vaccines
por: Liang, Yongjun, et al.
Publicado: (2021)

The dawn of mRNA vaccines: The COVID-19 case
por: Verbeke, Rein, et al.
Publicado: (2021)

Myocarditis Associated with mRNA COVID-19 Vaccination
por: Starekova, Jitka, et al.
Publicado: (2021)

Myocarditis after Covid-19 mRNA Vaccination
por: Verma, Amanda K., et al.
Publicado: (2021)

Myocarditis following COVID-19 mRNA vaccination
por: Parmar, Kanak, et al.
Publicado: (2021)

COVID-19 mRNA Vaccine-induced Pneumonitis
por: Matsuzaki, Shinichi, et al.
Publicado: (2021)

COVID-19 mRNA Vaccine-Associated Myocarditis
por: Kyaw, Htin, et al.
Publicado: (2022)

mRNA vaccines for COVID-19 and diverse diseases
por: Hussain, Abid, et al.
Publicado: (2022)

mRNA Covid-19 Vaccines in Pregnant Women
por: Riley, Laura E.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fp9398t7q7n52r9e615jrd613e